SCHEMBL8877346

SCHEMBL8877346

c1ccc(P(C23CC4CC(CC(C4)C2)C3)C23CC4CC(CC(C4)C2)C3)c(N2CCOCC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.42
ALDH1A1 P00352 5/20 0.38
NPSR1 Q6W5P4 2/20 0.38
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
MAPT P10636 5/20 0.38
MEN1 O00255 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.38
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
CNR2 P34972 3/20 0.35
CNR1 P21554 2/20 0.35
POLB P06746 1/20 0.35
HTR7 P34969 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19469284 0.99 EPHX2 (0.41) EPHX2ALDH1A1NPSR1DDB1CRBN
SCHEMBL8876593 0.87 KEAP1 (0.39) ALDH1A1NPSR1MAPTMEN1NPC1
SCHEMBL8875976 0.87 ALDH1A1 (0.38) ALDH1A1NPSR1MAPTMEN1KMT2A
SCHEMBL8877389 0.85 KEAP1 (0.41) ALDH1A1NPSR1MAPTMEN1NPC1
SCHEMBL8875969 0.85 KEAP1 (0.41) ALDH1A1NPSR1MAPTMEN1NPC1
SCHEMBL14755288 0.84 DDB1 (0.35) EPHX2ALDH1A1DDB1CRBNMAPT
SCHEMBL8883305 0.84 ALDH1A1 (0.36) ALDH1A1NPSR1MAPTMEN1KMT2A
SCHEMBL8877384 0.83 SIGMAR1 (0.47) ALDH1A1NPSR1MAPTMEN1KMT2A
SCHEMBL8881580 0.83 SIGMAR1 (0.47) ALDH1A1MAPTLMNAHSD17B10HTR7
SCHEMBL8877351 0.83 EPHX2 (0.32) EPHX2ALDH1A1NPSR1SMN1; SMN2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688717-A1 PALLADIUM-CATALYZED CHEMOSELECTIVE MONO-ALPHA-ARYLATION OF O-PROTECTED HYDROXYACETONE Bayer Aktiengesellschaft (DE) 2026-02-11 EP claimed
US-20250197380-A1 PHARMACEUTICAL INTERMEDIATE AND SYNTHESIS METHOD, AND ISOQUINOLINE DERIVATIVE AND SYNTHESIS METHOD THEREFOR BANGENTAI(SHANDONG) BIOSCIENCES GROUP SHARE CO., LTD. (CN) 2025-06-19 US claimed
CN-120136877-A Synthesis method of 6-chloro-2, 8-dimethylimidazo [1,2-B ] pyridazine 扬州联澳生物医药有限公司 2025-06-13 CN claimed
WO-2025123046-A1 SYNTHESIS OF LEUCINE-RICH REPEAT KINASE 2 MODULATORS ARVINAS OPERATIONS, INC. (US) 2025-06-12 WO claimed
CN-119731143-A Process for the preparation of biobased olefins from primary alcohols 巴斯夫欧洲公司 2025-03-28 CN claimed
CN-119504737-A Synthesis method of liseproof and intermediate thereof 扬州联澳生物医药有限公司 2025-02-25 CN claimed
US-12233402-B2 Cross-coupling reaction catalysts, and methods of making and using same YALE UNIVERSITY (US) 2025-02-25 US claimed
WO-2025036129-A1 METHOD FOR SYNTHESIZING RISDIPLAM INTERMEDIATE AND RISDIPLAM INTERMEDIATE 扬州联澳生物医药有限公司 2025-02-20 WO claimed
US-20250002519-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME UNIV YALE (US) 2025-01-02 US claimed
WO-2024200462-A1 PALLADIUM-CATALYZED CHEMOSELECTIVE MONO-α-ARYLATION OF O-PROTECTED HYDROXYACETONE BAYER AKTIENGESELLSCHAFT (DE) 2024-10-03 WO claimed
CN-114105922-A Synthesis method of hydroxypropyl tetrahydropyrane triol 北京富盛嘉华医药科技有限公司 2022-03-01 CN claimed
US-20210061834-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME NATIONAL SCIENCE FOUNDATION 2021-03-04 US claimed
EP-3736279-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME Yale University (US) 2020-11-11 EP claimed
EP-3204395-B1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME UNIV YALE (US) 2020-05-27 EP claimed
EP-3601307-A1 CROSS-COUPLING REACTION CATALYSTS, AND METHODS OF MAKING AND USING SAME Yale University (US) 2020-02-05 EP claimed
WO-2018183328-A1 CROSS-COUPLING REACTION CATALYSTS, AND METHODS OF MAKING AND USING SAME YALE UNIVERSITY (US) 2018-10-04 WO claimed
US-20170305948-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME UNIV YALE (US) 2017-10-26 US claimed
EP-3204395-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME Yale University (US) 2017-08-16 EP claimed
WO-2016057600-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME YALE UNIVERSITY (US) 2016-04-14 WO claimed
US-9233922-B2 Process for producing N-(hetero)arylazoles TAKASAGO INTERNATIONAL CORPORATION (JP) 2016-01-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002519-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME TIMCC, YAP1, TET2 EPHX2 166/4885ALDH1A1 1759/4885NPSR1 4319/4885
US-20210061834-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME TIMCC, YAP1, TET2 EPHX2 166/4885ALDH1A1 1759/4885NPSR1 4319/4885
US-20250197380-A1 PHARMACEUTICAL INTERMEDIATE AND SYNTHESIS METHOD, AND ISOQUINOLINE DERIVATIVE AND SYNTHESIS METHOD THEREFOR PARK7, SQLE, CYP4F11 EPHX2 1746/4885ALDH1A1 951/4885NPSR1 1200/4885
US-20170305948-A1 NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME TIMCC, YAP1, TET2 EPHX2 166/4885ALDH1A1 1759/4885NPSR1 4319/4885
US-12233402-B2 Cross-coupling reaction catalysts, and methods of making and using same TET2, TIMCC, MDM4 EPHX2 118/4885ALDH1A1 1625/4885NPSR1 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.